

Paxlovid (nirmatrelvir/ritonavir) Referral Form

Instructions:

1. Please read and complete the below sections.
2. Fax completed pages 1 and 2 of this form, Patient Demographics, and prescription to **724-308-5722** to schedule patient.

Indications:

For the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with a positive results of SARS-CoV-2 viral tests and/or a current diagnosis of mild-to-moderate coronavirus disease 2019 (COVID-19):

- Who are at high risk of progression to severe COVID-19, including hospitalization or death, AND
- within 5 days of symptom onset.

Section 1:

Patient Name: _____ Date of Birth: _____

Allergies: _____ Patient Phone: _____

Weight (include units): _____ Height (include units): _____ Gender: M F

Referring Provider: _____ Provider Contact: _____

Received or scheduled to receive COVID-19 vaccination ____ Yes ____ No; if yes, when _____

Section 2:

Medical History:

- Positive test for SARS-CoV-2; date of positive test: _____
- Current diagnosis of mild to moderate COVID-19
- Onset of symptoms within past 5 days
- Age \geq 18 years OR $>$ 12 years of age and weighing at least 40 kg
- High risk of progression to severe COVID-19, including hospitalization or death
- Not requiring hospitalization due to severe or critical COVID-19 at treatment initiation
- No known or suspected severe renal impairment (eGFR $<$ 30 mL/min). Note that a dose reduction is required for patients with moderate renal impairment (eGFR \geq 30- $<$ 60 mL/min); see the Fact Sheet for Healthcare Providers.
- No known or suspected severe hepatic impairment (Child-Pugh Class C)
- No history of clinically significant hypersensitivity reactions [e.g., toxic epidermal necrolysis (TEN) or Stevens-Johnson syndrome] to the active ingredients (nirmatrelvir or ritonavir) or other components of the product

Section 3:

Eligibility Criteria:

- The patient has the following underlying medical condition(s) associated with higher risk for severe COVID-19 ([Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals | CDC](#)):

Section 4:

Please indicate if the patient takes any of the following **concomitant medications** and the appropriate actions (including patient instruction) were completed by the prescribing prescriber.

- HMG-CoA reductase inhibitors (statins)
 - Patient is taking lovastatin or simvastatin, which are contraindicated with PAXLOVID coadministration: Patient instructed to hold the statin 12 hours prior to the first dose of PAXLOVID treatment, hold during the 5 days of treatment, and restart 5 days after completing PAXLOVID.

- Patient is taking atorvastatin or rosuvastatin: Patient instructed to temporary discontinue atorvastatin and rosuvastatin during treatment with PAXLOVID. Atorvastatin and rosuvastatin do not need to be held prior to or after completing PAXLOVID.
- Hormonal contraceptives containing ethinyl estradiol: Patient is taking a hormonal contraceptive containing ethinyl estradiol: Patient instructed on the need for an additional non-hormonal method of contraception during the 5 days of PAXLOVID treatment and until one menstrual cycle after stopping PAXLOVID.
- Medications for HIV-1 Treatment: Patient is taking medications for the treatment of HIV-1 infection: With the exception of maraviroc³, HIV antiretroviral medications can be co-administered with PAXLOVID without dose adjustment, but arranging follow-up by the HIV care provider to monitor for side effects is recommended.

Section 4:

Please review the attached "Other Drugs with Established and Other Potentially Significant Drug Interactions with PAXLOVID" document and choose one of the following options:

- Patient is not taking any of the medications.
- Patient is taking one or more of the medications listed in YELLOW, and dose adjustment, holding of medication, or increased monitoring is planned.
- Patient is taking one or more of the medications listed in RED and coadministration of PAXLOVID is CONTRAINDICATED.

Section 5:

Referring licensed prescribing attestation (must be checked to be eligible for treatment).

- Paxlovid (nirmatrelvir 300 mg /ritonavir 100 mg) by mouth twice daily for 5 days
- Paxlovid (nirmatrelvir 150 mg /ritonavir 100 mg) by mouth twice daily for 5 days for patients with moderate renal impairment (eGFR \geq 30-<60 mL/min).

Prescriber must indicate all the following requirements have been met:

- An electronic or hardcopy of The Fact Sheet for Patients and Caregivers was provided and reviewed with the patient/caregiver
- Patient/caregiver has been informed that the medication is an unapproved drug that is authorized under an Emergency Use Authorization
- Patient/caregiver informed of alternatives to receiving this medication
- Patient/caregiver informed of the risks and benefits of taking this medication
- Patient aware of risks, benefits, and alternatives and agrees to proceed with treatment.

Provider Printed Name: _____

Provider Signature: _____

Date: _____

Other Drugs with Established and Other Potentially Significant Drug Interactions with PAXLOVID (listed alphabetically by generic name)

Drugs listed in this table are a guide and are not considered a comprehensive list of all possible drugs that may interact with PAXLOVID. The healthcare provider should consult other appropriate resources such as the prescribing information for the interacting drug for comprehensive information on dosing or monitoring with concomitant use of a strong CYP3A inhibitor such as ritonavir.

Interaction Codes:



Coadministration of this drug with PAXLOVID is CONTRAINDICATED. For further information, refer to the Fact Sheet for Healthcare Providers and the individual Prescribing Information for the drug.



Coadministration of this drug with PAXLOVID should be avoided and/or holding of this drug, dose adjustment of this drug, or special monitoring is necessary. Consultation with the prescriber of the potentially interacting drug is recommended. For further information, refer to the Health Care Provider Fact Sheet and the individual Prescribing Information for the drug.

Drug	Drug Class	Interaction Code
abemaciclib	Anticancer drug	***
alfuzosin	Alpha 1-adrenoreceptor antagonist	XXX
aliskiren	Cardiovascular agent	***
amiodarone	Antiarrhythmic	XXX
amlodipine	Calcium channel blocker	***
apalutamide	Anticancer drug	XXX
apixaban	Anticoagulant	***
aripiprazole	Neuropsychiatric agent	***
avanafil	PDE5 inhibitor	***
bedaquiline	Antimycobacterial	***
betamethasone	Systemic corticosteroid	***
brexpiprazole	Neuropsychiatric agent	***
bosentan	Endothelin receptor antagonist	***
budesonide	Systemic corticosteroid	***
bupropion	Antidepressant	***

Drug	Drug Class	Interaction Code
bupirone	Sedative/hypnotic	***
carbamazepine	Anticonvulsant	XXX
cariprazine	Neuropsychiatric agent	***
ceritinib	Anticancer drug	***
ciclesonide	Systemic corticosteroid	***
cilostazol	Cardiovascular agent	***
clarithromycin	Anti-infective	***
clonazepam	Anticonvulsant	***
clorazepate	Sedative/hypnotic	***
clopidogrel	Cardiovascular agent	***
clozapine	Antipsychotic	***
colchicine	Anti-gout	XXX
cyclosporine	Immunosuppressant	***
dabigatran	Anticoagulants	***
darifenacin	Muscarinic receptor antagonist	***
dasabuvir	Hepatitis C direct acting antiviral	***
dasatinib	Anticancer drug	***
dexamethasone	Systemic corticosteroid	***
diazepam	Sedative/hypnotic	***
digoxin	Cardiac glycoside	***
dihydroergotamine	Ergot derivative	XXX
diltiazem	Calcium channel blocker	***
disopyramide	Antiarrhythmic	***
dronedarone	Antiarrhythmic	XXX
elbasvir/grazoprevir	Hepatitis C direct acting antiviral	***
eletriptan	Migraine medication	XXX
elexacaftor/tezacaftor/ivacaftor	Cystic fibrosis transmembrane conductance regulator potentiator	***
encorafenib	Anticancer drug	***
eplerenone	Cardiovascular agent	XXX
ergotamine	Ergot derivative	XXX
erythromycin	Anti-infective	***
estazolam	Sedative/hypnotic	***
everolimus	Immunosuppressant	***
felodipine	Calcium channel blocker	***
fentanyl	Narcotic analgesic	***

finerenone	Mineralocorticoid receptor antagonist	XXX
flecainide	Antiarrhythmic	XXX
flurazepam	Sedative/hypnotic	***
fluticasone	Systemic corticosteroid	***
flibanserin	Serotonin receptor 1A agonist/ serotonin receptor 2A antagonist	XXX

Drug	Drug Class	Interaction Code
glecaprevir/pibrentasvir	Hepatitis C direct acting antiviral	***
hydrocodone	Narcotic analgesic	***
ibrutinib	Anticancer drug	***
iloperidone	Neuropsychiatric agent	***
isavuconazonium sulfate	Antifungal	***
itraconazole	Antifungal	***
ivabradine	Cardiovascular agent	XXX
ivacaftor	Cystic fibrosis transmembrane conductance regulator potentiator	***
ivosidenib	Anticancer drug	***
ketoconazole	Antifungal	***
lidocaine (systemic)	Antiarrhythmic	***
lomitapide	Microsomal triglyceride transfer protein (MTTP) inhibitor	XXX
lumacaftor/ivacaftor	Cystic fibrosis transmembrane conductance regulator potentiator	XXX
lumateperone	Neuropsychiatric agent	***
lurasidone	Antipsychotic	XXX
meperidine	Narcotic analgesic	***
methadone	Narcotic analgesic	***
methylergonovine	Ergot derivative	XXX
methylprednisolone	Systemic corticosteroid	***
midazolam (administered parentally)	Sedative/hypnotic	***
midazolam (oral)	Sedative/hypnotic	XXX
mometasone	Systemic corticosteroid	***
naloxegol	Opioid antagonist	XXX
neratinib	Anticancer drug	***
nicardipine	Calcium channel blocker	***
nifedipine	Calcium channel blocker	***
nilotinib	Anticancer drug	***
ombitasvir/paritaprevir /ritonavir	Hepatitis C direct acting antiviral	***

oxycodone	Narcotic analgesic	***
phenobarbital	Anticonvulsant	XXX
phenytoin	Anticonvulsant	XXX
pimavanserin	Neuropsychiatric agent	***
pimozide	Antipsychotic	XXX
primidone	Anticonvulsant	XXX
propafenone	Antiarrhythmic	XXX
quetiapine	Antipsychotic	***
quinidine	Antiarrhythmic	XXX
ranolazine	Antianginal	XXX
rifabutin	Antimycobacterial	***
rifampin	Antimycobacterial	XXX
Drug	Drug Class	Interaction Code
rifapentine	Antimycobacterial	***
rimegepant	Migraine medication	***
riociguat	sGC stimulator	***
rivaroxaban	Anticoagulant	***
salmeterol	Long-acting beta-adrenoceptor agonist	***
saxagliptin	DPP4 inhibitor	***
Sildenafil (when used for erectile dysfunction)	PDE5 inhibitor	***
sildenafil (Revatio®) when used for pulmonary arterial hypertension	PDE5 inhibitor	XXX
silodosin	Benign prostatic hyperplasia agent	XXX
sirolimus	Immunosuppressant	***
sofosbuvir/velpatasvir/ voxilaprevir	Hepatitis C direct acting antiviral	***
St. John's Wort (hypericum perforatum)	Herbal product	XXX
suvorexant	Neuropsychiatric agent	***
tacrolimus	Immunosuppressant	***
tadalafil	PDE5 inhibitor	***
tamsulosin	Alpha 1-adrenoreceptor antagonist	***
tezacaftor/ivacaftor	Cystic fibrosis transmembrane conductance regulator potentiator	***
ticagrelor	Cardiovascular agent	***
tofacitinib	JAK inhibitor	***
tolvaptan	Vasopressin receptor antagonist	XXX
trazodone	Antidepressant	***
triamcinolone	Systemic corticosteroid	***

triazolam	Sedative/hypnotic	XXX
ubrogepant	Migraine medication	XXX
upadacitinib	JAK inhibitor	***
vardenafil	PDE5 inhibitor	***
venetoclax	Anticancer drug	***
verapamil	Calcium channel blocker	***
vinblastine	Anticancer drug	***
vincristine	Anticancer drug	***
voclosporin	Immunosuppressant	XXX
vorapaxar	Cardiovascular agent	***
voriconazole	Antifungal	***
warfarin	Anticoagulant	***
zolpidem	Sedative/hypnotic	***

ADDITIONAL RESOURCES:

PAXLOVID - Fact Sheet for Healthcare Providers: [Emergency Use Authorization | FDA](#)

Prescribing Information (Label/Package Insert) for Individual Drugs (Drugs@FDA):
<https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm>

University of Liverpool COVID-19 Drug Interactions: <https://www.covid19-druginteractions.org/checker>

NIH COVID-19 Treatment Guidelines: <https://www.covid19treatmentguidelines.nih.gov/therapies/antiviral-therapy/ritonavir-boosted-nirmatrelvir--paxlovid/>